Merck & Co., Inc: Pulmonary Disease, Chronic Obstructive trials
The registry lists 26 Pulmonary Disease, Chronic Obstructive studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 15 have results posted.
Phase 1 3Phase 2 18Phase 3 4Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)RecruitingNCT07874815Phase 3
- A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPDCompletedNCT06545500Phase 2Results posted
- Effect of Ensifentrine Treatment on CAT ScoreCompletedNCT06460493Phase 3Results posted
- A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDCompletedNCT04542057Phase 3Results posted
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDCompletedNCT04535986Phase 3Results posted
- A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary DiseaseCompletedNCT04091360Phase 2Results posted
- Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder InhalerCompletedNCT04027439Phase 2Results posted
- Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDCompletedNCT03937479Phase 2Results posted
- Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPDCompletedNCT03673670Phase 2Results posted
- Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT03443414Phase 2Results posted
- The Effects of RPL554 in Addition to Tiotropium in COPD PatientsCompletedNCT03028142Phase 2Results posted
- Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)CompletedNCT01293006Phase 1Results posted
- Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)TerminatedNCT01006616Phase 2Results posted
- Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)TerminatedNCT00441701Phase 2Results posted
- Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)TerminatedNCT00387036Phase 2Results posted
- An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)TerminatedNCT00132730Phase 2Results posted
- A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT07132983Phase 2
- Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)CompletedNCT07016412Phase 2
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPDActive, not recruitingNCT05612035Phase 2
- Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)Active, not recruitingNCT05270525Phase 2
- The Effects of RPL554 on Top of Standard COPD Reliever MedicationsCompletedNCT02542254Phase 2
- SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsCompletedNCT02307162Phase 1
- Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)TerminatedNCT01068145Phase 1
- A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)CompletedNCT00482235Phase 2
- A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)CompletedNCT00418613Phase 2
- Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)CompletedNCT00139932Phase 4